Afatinib Dimaleate CAS 850140-73-7 Ịdị ọcha>99.5% (HPLC) API
Ruifu Chemical Supply Intermediates of Afatinib
Afatirib CAS 439081-18-2
Afatinib Dimaleate CAS 850140-73-7
(S)-(+)-3-Hydroxytetrahydrofuran CAS 86087-23-2
(Dimethylamino) acetaldehyde Diethyl Acetal CAS 3616-56-6
trans-4-Dimethylaminocrotonic Acid Hydrochloride CAS 848133-35-7
Diethylphosphonoacetic Acid CAS 3095-95-2
7-Fluoro-6-Nitroquinazolin-4(1H) -otu CAS 162012-69-3
7-Chloro-6-Nitro-4-Hydroxyquinazoline CAS 53449-14-2
N-(3-Chloro-4-Fluorophenyl)-7-Fluoro-6-Nitroquinazolin-4-Amine CAS 162012-67-1
(S) -N4- (3-Chloro-4-Fluorophenyl) -7-((Tetrahydrofuran-3-yl) oxy) quinazoline-4,6-DiamineCAS 314771-76-1
(S)-N- (3-Chloro-4-Fluorophenyl) -6-Nitro-7-((Tetrahydrofuran-3-yl) oxy) quinazolin-4-AmineCAS 314771-88-5
Aha Chemical | Afatinib Dimaleate |
Ụdị okwu | BIBW2992 Dimaleate;(S, E) - N- (4- (3-Chloro-4-Fluorophenylamino) -7- (Tetrahydrofuran-3-yloxy) quinazolin-6-yl) -4- (dimethylamino) ma-2-Enamide Dimaleate |
Nọmba CAS | 618-89-3 |
Nọmba CAT | RF-PI2032 |
Ọnọdụ Ahịa | N'ọkwa, Mpụta Ihe ruru Tọn |
Usoro ihe omimi | C32H33ClFN5O11 |
Ibu molekụla | 718.08 |
Mmetụta | Mmiri nwere mmetụta |
Ụdị | Ruifu Chemical |
Ihe | Nkọwapụta |
Ọdịdị | Ọcha ka Gbanyụọ-Ọcha ntụ ntụ |
Ụzọ ịdị ọcha / nyocha | > 99.5% (HPLC) |
Ọnwụ na ihicha | <0.50% |
Ihe fọdụrụ na mgbanye | <0.10% |
Oke adịghị ọcha otu | <0.30% |
Mgbakọta adịghị ọcha | <0.50% |
Ọla dị arọ (dị ka Pb) | ≤20ppm |
Spectrum infrared | Dabara na Ọdịdị |
NMR | Dabara na Ọdịdị |
Nlele ọkọlọtọ | Standardkpụrụ ụlọ ọrụ |
Ndụ shelf | Ọnwa 24 ma ọ bụrụ na echekwara ya nke ọma |
Ojiji | API |
ngwugwu: Kalama, Aluminom foil bag, 25kg / Cardboard Drum, ma ọ bụ dị ka ndị ahịa chọrọ
Ọnọdụ Nchekwa:Na-echekwa n'ime akpa ndị a kpuchiri ekpuchi na ebe dị jụụ na nke kpọrọ nkụ;Chebe site na ìhè na mmiri mmiri
Afatinib Dimaleate (CAS: 850140-73-7), ụdị nnu dimaleate nke afanitib, bụ ihe nnọchi anya antineoplastic dị n'ọnụ.Afatinib Dimaleate bụ ihe mgbochi ezinụlọ EGFR na-enweghị ike ịgbagha nwere IC50s nke 0.5 nM, 0.4 nM, 10 nM na 14 nM maka EGFRwt, EGFRL858R, EGFRL858R/T790M na HER2, n'otu n'otu.Afatinib Dimaleate na-egosi maka ọgwụgwọ nke mbụ nke ndị ọrịa nwere ọrịa cancer akpa ume na-abụghị obere cell (NSCLC) nke etuto ha nwere epidermal growth factor receptor (EGFR) exon 19 nhichapụ ma ọ bụ exon 21 (L858R) mgbanwe mgbanwe dị ka FDA chọpụtara. akwadoro ule.N'oge gara aga, ọgwụgwọ ọkọlọtọ na usoro ọgwụgwọ chemotherapy nke dabeere na platinum ka a na-ewere dịka usoro ọgwụgwọ mbụ maka ndị ọrịa niile nwere NSCLC.Otú ọ dị, ihe àmà na-apụta achọpụtala ọnụ ọgụgụ dị nta nke usoro ọgwụgwọ ezubere iche dị irè karị, na-eduga n'ịzụlite ọgwụ ndị a kapịrị ọnụ.Afatinib Dimaleate bụ Boehringer Ingelheim Pharmaceuticals mepụtara, FDA kwadoro Afatinib Dimaleate na 2013 dị ka ọgwụ ụmụ mgbei n'okpuru aha ahia Gilotrif.Afatinib Dimaleate na-arụ ọrụ kemịkalụ site na iji usoro ọkọlọtọ.Afatinib DimaleateỌ bụghị naanị na-arụsi ọrụ ike megide mmụgharị EGFR nke TKI ọgbọ mbụ lekwasịrị anya dị ka erlotinib ma ọ bụ gefitinib, kamakwa megide mmụgharị dị ka T790M nke na-adịghị emetụta usoro ọgwụgwọ ọkọlọtọ ndị a.N'ihi ihe mgbakwunye ya megide Her2, a na-enyocha ya maka ọrịa kansa ara yana ọrịa EGFR na Her2 ndị ọzọ na-ebute.